A pilot study of the safety and efficacy of ALX-0600 in subjects with moderately active Crohn's disease

Trial Profile

A pilot study of the safety and efficacy of ALX-0600 in subjects with moderately active Crohn's disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Teduglutide (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors NPS Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Nov 2015 Status changed from active, no longer recruiting to completed as per NCT.
    • 22 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top